Dishman Carbogen Amcis Limited
Incorporated in 1983, DCAL is an integrated CRAMS player. The company operates 25 multipurpose facilities across India, Switzerland, France, the Netherlands, the UK and China, and a dedicated production facility for APIs and intermediates each in Bav...
Key Metrics
EPS
-9.79
Current ratio
0.75
Debt/Equity
0.50
Debt/EBITDA
9.11
Interest coverage ratio
-0.02
Operating Cashflow to total debt
0.14
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Diversified Business Profile
Improved Revenue Visibility owing to Past Capex and Successful Inspection Closures.
Liquidity Indicator - Adequate
Cons
Overall Weak Operational Performance during FY23, Impacted due to Currency Movements
Modest Credit Metrics
Stretched Working Capital Cycle; High Maintenance Capex Requirements
Moderate Forex Risk
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Dishman Carbogen Amcis Limited bond.
This comprehensive profile covers key factual information about DISHMAN CARBOGEN AMCIS LIMITED. Incorporated in 1983, DCAL is an integrated CRAMS player. The company operates 25 multipurpose facilities across India, Switzerland, France, the Netherlands, the UK and China, and a dedicated production facility for APIs and intermediates each in Bavla and Naroda (Gujarat). DCAL’s multi-purpose manufacturing facilities at 10 sites have been approved by global health authorities, some of which are United States Food and Drug Administration, Swissmedic and Pharmaceuticals and Medical Devices Agency. EPS in Mar-2024 was -9.79. Current ratio in Mar-2024 was 0.75. Debt/Equity in Mar-2024 was 0.50. Debt/EBITDA in Mar-2024 was 9.11. Interest coverage ratio in Mar-2024 was -0.02. Operating Cashflow to total debt in Mar-2024 was 0.14. Total revenue for Mar-2025 was ₹2639.91. Net income for Mar-2025 stood at ₹97.72. Total assets as of Mar-2024 were ₹9570.62. Operating cash flow for Mar-2024 was ₹383.97. The company’s borrowing relationships include Bank of Baroda (₹N/A Cr), Bank of Baroda (₹N/A Cr), Bajaj Finance (₹N/A Cr), Axis Bank Limited (₹N/A Cr), State Bank of India (₹N/A Cr), Bank of Baroda (₹N/A Cr), Union Bank of India (₹N/A Cr), IDFC First Bank (₹N/A Cr), Indian Bank (₹N/A Cr), HDFC Bank Limited (₹N/A Cr), Axis Bank Limited (₹N/A Cr), DCB Bank (₹N/A Cr), State Bank of India (₹N/A Cr), Bank of Baroda (₹N/A Cr), Union Bank of India (₹N/A Cr), IDFC First Bank (₹N/A Cr), IDFC First Bank (₹N/A Cr), Bandhan Bank (₹N/A Cr). Peers and comparison entities consist of DISHMAN CARBOGEN AMCIS LIMITED, Divi's Laboratories Limited, Syngene International Limited, Aarti Pharmalabs Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Diversified Business Profile; Improved Revenue Visibility owing to Past Capex and Successful Inspection Closures.; Liquidity Indicator - Adequate; . Key risks include: Overall Weak Operational Performance during FY23, Impacted due to Currency Movements; Modest Credit Metrics; Stretched Working Capital Cycle; High Maintenance Capex Requirements; Moderate Forex Risk. Leadership team details include Alan Fischer (Chief Technology Officer), Arpit J Vyas (Global Managing Director), Deohooti J Vyas (Whole Time Director), Dieter Thueer (Global Head - HR), Harshil Dalal (Global Chief Financial Officer), Janmejay R Vyas (Chairman), Maitri K Mehta (Independent Director), Paolo Armanino (Chief Operating Officer), Pascal Villemagne (Chief Executive Officer), Rajendra S Shah (Independent Director), Shrima G Dave (Company Secretary & Compliance Officer), Stephan Fritschi (Executive Vice President), Subir Kumar Das (Independent Director). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.